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This study analysed the impact on palliative care outcomes of a new specialist palliative 
care service for patients severely affected by amyotrophic lateral sclerosis (ALS/MND), 
multiple sclerosis, WĂƌŬŝŶƐŽŶ ?Ɛ disease and related disorders (multiple system atrophy 
progressive supranuclear palsy, MSA-PSP). 
 
Methods  
The design followed the Medical Research Council Framework for the evaluation of complex 
interventions. A phase II randomised controlled trial (RCT) was undertaken comparing an 
immediate referral to the service (FT, fast track) to a 16-week wait (standard track (ST), 
standard best practice) using a parallel arm design. The main outcome measures were 
Quality of Life (measured with Schedule for the Evaluation of Individual Quality of Life 
Direct Weight, SEIQoL- DW) and burden of the carers (Caregivers Burden Inventory, CBI), 
with secondary outcomes of symptoms, psychosocial and spiritual issues. 
 
Results 
50 patients severely affected by neurodegenerative conditions and their informal family 
carers were randomized: 25 FT, 25ST. At baseline (T0) there were no differences between 
groups. 4 patients died during the follow-up (2 FT, 2 ST) and 2 patients dropped out before 
the end of the study.After 16 weeks (T1), Ft participants scored significant improvement in 
the SEIQoL-DW index, pain, dyspnea, sleep disturbance and bowel symptoms. 
 
Conclusions 
This exploratory RCT provides evidence that no harm was experienced by SPCS for patients 
severely affected by neurodegenerative disorders. There was an improvement in quality of 
life and physical symptoms for neurological patients in palliative care. Caregiver burden 
















Palliative care aims at improving quality of life (QoL) of patients and their families facing 
problems associated with incurable, progressive and life-limiting disease by means of the 
impeccable assessment and treatment of symptoms and other psycho- logical, social and 
spiritual issues.1 Patients affected by progressive neurodegenerative conditions suffer a high 
burden of symptoms2 3 and issues that are often managed by specialist palliative care teams.4 
However, there is a challenge in providing specialist palliative care service (SPCS) for individuals 
with advanced neurological conditions as there is a great variability in disease trajectories and 
symptom profiles. This has been considered in the discussion of the provision of palliative and 
end ? of-life care for this patient group,4 and there is evidence that the suggested triggers for 
consideration of care may be of help ?  these being patient request, family request, dysphagia, 
cognitive decline, dyspnoea, repeated infections (in particular, aspiration pneumonia), weight 
loss and marked decline in condition.4 5  
 
Although SPCS has been advocated in the care of patients with neurological dis- eases,6 there 
is very little available evidence about the impact of SPCS on the typical palliative care 
outcomes. Moreover, there is little definitive evidence for the effectiveness of palliative care 
generally. One review has shown that the evidence for benefit from specialised palliative care 
is sparse and limited by methodological shortcomings.7 Carefully planned trials, using a 
standardized palliative care intervention and measures constructed specifically for this 
population, are needed. One project ? ENABLE 28 ? did show in an randomised controlled trial 
(RCT) that QoL and depression were improved by the SPCS in patients with advanced cancer, 
even though the physical symptoms were not. A literature review suggested that SPCSs 
provide sigŶŝĨŝĐĂŶƚďĞŶĞĨŝƚƐŽŶƉĂƚŝĞŶƚƐ ?ƉĂŝŶĂŶĚŽƚŚĞƌ symptoms for patients with advanced 
cancer.9 
 
Within the care of people with neurological conditions, there has been little research, although 
one study, an RCT using a delayed intervention model, did show that early specialist palliative 
care did help people with multiple sclerosis (MS). There were positive results for the 
management of nausea and sleeping problems to some degree, with the effect strongest after 
initial contact with the clinical service. There was also a positive impact on informal carer well- 
being and user satisfaction with the service was high among patients with MS, carers and 
especially other healthcare professionals.10 11 No studies were found in the literature exploring 
the impact of an SPCS for people severely affected by amyotrophic lateral sclerosis/motor 
ŶĞƵƌŽŶĞ ĚŝƐĞĂƐĞ  ?>^ ?DE ? ? D^ Žƌ WĂƌŬŝŶƐŽŶ ?Ɛ ĚŝƐĞĂƐĞ  ?W ? ǁŚĞŶ ĐŽŶƐŝĚĞƌĞĚ ĂƐ Ă ǁŚŽůĞ
group of people with progressive neurological patients (refs. 12 and 13, p.220). 
 
The aim of this project is to investigate if the involvement of SPCS would affect individual QoL 
of patients severely affected by neurodegenerative conditions and the burden of care of their 




The study adopted a phase 2 pilot RCT14  using  the fast track (FT) versus standard track (ST) 
design, also called the waiting list study, adapted from a previous study on MS.15 This allowed 








Participants were adults severely affected by ALS/ MND, MS or PD. Informal family carers of the 
patients were also enrolled if they wished. Patients were resident in Turin city or in the 
metropolitan area as this was the area where the SPCS ? Fondazione Assistenza e Ricerca 
Oncologia (FARO) ? is able to provide care. The severity of the disease was defined according to 
the Gold Standards Framework prognostic indicators specific for the different conditions16 as 
shown in table 1 ? ALS/MND severe disease, MS Expanded Disability Status Scale17 equal to or 
greater than 8.5, PD Hoehn and Yahr18 A? ? ?WĂƌƚŝĐŝƉĂŶƚƐǁĞƌĞĞǆĐůƵĚĞĚŝĨƚŚĞŝŶĐůƵƐŝŽŶĐƌŝƚĞƌŝĂ
were not satisfied, if the cognitive state was compromised so that they could not complete the 
outcome measures (augmentative or alternative communication aids were incentivised where 
possible) or if consent to participation was refused. If the informal family carer was not available 
or the patient did not wish their participation, only the patient was enrolled. 
 
Participants were referred to the study by the medical specialists working in the tertiary clinics for 
the specific neurological disease groups of two main hospitals of Turin. As this was a pilot RCT, no 
sample size based on the statistical calculation was calculated a priori, and a sample of 50 
participants, allocated 25/ group, was chosen as it was estimated that this increase in the number 
of patients could be coped with by the existing palliative care service. 
 
Every week, two patients with the same disease and similar clinical features (eg, both with 
ALS/MND and receiving non-invasive ventilation) were assessed at baseline (T0), and then 
randomised one to the FT group and the other to the ST group using a parallel arm design. The 
randomisation was undertaken by placing two unrecognisable white folders, containing the two 
ƉĂƚŝĞŶƚƐ ?ĐŚĂƌƚƐ ?ŽŶĂƐĞĐƌĞƚĂƌǇ ?ƐĚĞƐŬ ?dŚĞƐĞĐƌĞƚĂƌǇǁĂƐĂƐŬĞĚƚŽƉŝĐŬƵƉŽŶĞƌĂŶĚŽŵůǇĂŶĚƚŚŝƐ
was chosen as the FT patient, the other patient went into the ST group. Patients allocated in the 
FT group received the SPCS immediately, whereas those allocated in the ST group waited 16 
weeks (T1) before receiving the palliative care input ? figure 1 (loaded as a separate file). After T1 
all the participants could receive the SPCS, if they wished, for as long as necessary. Participants 
randomised to the ST group had a waiting list of 16 weeks after allocation, and during this period 
they received the standard care, provided by primary medicine and hospital specialists. Patients 
were asked to identify their main informal caregiver and to decide whether they could be 
involved and complete the tools for caregivers. 
 
The SPCS was provided by FARO Foundation,19 which provided a team, trained and expert in 
palliative care, comprising a physician, a nurse, a psychologist and a physiotherapist. The team 
members visit the patients and the family on a regular basis depending on the palliative care 
needs and issues that are assessed in that assistance. On average, patients are seen at least 
weekly by a team member and all patients are discussed at a team meeting every 2 weeks. 
Volunteers are also available if social support is required. The team can assess symptoms, 
prescribe medications, provide nursing care and physical therapies as well as psychological 
support and bereavement care. Team members and study personnel could not be blind to 




The outcome measures were applied at T0 (before randomisation) and at T1 (when only the FT 




Quality   of   Life   Direct 
Weight (SEIQoL-DW),20 a validated tool to measure this ĚŽŵĂŝŶŝŶƚŚĞƐĞƉĂƚŝĞŶƚƐ ?ŐƌŽƵƉ ?21 ?23 
ھ &ĂŵŝůǇŝŶĨŽƌŵĂůĐĂƌĞƌƐ ?ďƵƌĚĞŶŽĨĐĂƌĞŵĞĂƐƵƌĞĚǁŝƚŚ 
the Caregiver Burden Inventory.24 
The secondary outcome measures were physical, psychological, social and spiritual issues 
that had particular relevance to this patient group in an earlier qualitative study.3 A full list of 




Analysis was undertaken from the outcome measures at baseline (T0), after 16 weeks (T1) and 
the difference between the mean scores (T1 ?T0). In order to appraise the potential benefit of 
the SPCS, clinical and statistical significance were considered. The SPSS 15 software package 
was used for data analysis. 
 
Clinical significance provides information on whether a treatment is effective enough to change 
ĂƉĂƚŝĞŶƚ ?ƐĚŝĂŐŶŽƐƚŝĐůĂďĞůŽƌƚŽŵĂŬĞĂƐŝŐŶŝĨŝĐĂŶƚĐŚĂŶŐĞŝŶĂƉĂƚŝĞŶƚ ?ƐĐŽŶĚŝƚŝŽŶ ?For pain and 
sleep disturbance, this change has been described as greater than 13% and 10%, respectively.28 
29 It has been suggested that a change of 50% of the SD  of  any  QoL tool can be considered a 
clinically significant change. This translates to a change of 8 ?10 points on a 100-points scale.30 
 
The clinical interpretation of the results in  this study has been categorised in three possible 
groups: 
ھ No clinical significance if the difference between T1 and T0 is lower than 10% of the scale 
used to measure that domain; 
ھ Moderate clinical significance if that difference  is  between 10 ?19% of the same scale; 
ھ Relevant clinical significance when the difference is 20% or higher. 
 
 
The statistical analysis included: 
 
x Descriptive statistics to evaluate the comparability of the two study groups 
x Group comparison test to detect differences between the two study groups that can 
be caused by the intervention. 
x The aim of this procedure is to determine the efficacy analysis. Depending on the 
characteristics of the vari- ables, the analysis of covariance (ANCOVA), independ- ent t 
ƚĞƐƚŽƌʖ2 test were used to highlight statistical changes between the two groups. 
x The null hypothesis of this study is that no changes are tobe found between the FTand 
ST groups after the interven- tion represented by the provision of the SPCS in the treated 
group versus the best standard care in the control group. 
x dŚĞɲǀĂůƵĞ ?ĚĞƚĞƌŵŝŶing the statistical significance foundin this study, is set at 0.05. 
Bonferroni adjustments were applied for the ANCOVA test of the variables which were 




As there was no existing service for people with progressive neurological disease, it was felt to 
be ethical to delay the service for 16 weeks for the control group, who were offered care at the 
end of this period. Patients in the control group who experienced symptoms at baseline were 




Ethical approval was obtained from the Ethics Committee of the two hospitals ? Department of 
Neuroscience, University of Torino and S. Luigi Gonzaga Hospital, Orbassano ? and the University of 







Demographics, recruitment, attrition, mortality 
 
From March 2008 to February 2009, 52 potential participants were referred to the study. Two 
participants refused to participate, both with MS: one did not feel seriously ill and for this 
reason did not want to be cared for by an SPCS; the other had recently been diagnosed with 
breast cancer and was going to start chemotherapy. Of the 50 patients enrolled, 30 (60%) were 
male and 20 (40%) female. The mean age was 61 years and 8 (16%) were aged under 44 years, 
17 (34%) 45 ?65 years and 25 (50%) over 65 years. The diagnosis was ALS/MND for 16 (32%),  
MS  for 18 (36%) and PD for 16 (32%). 
 
Five patients did not wish their carer to be involved, and so 45 family carers were included in 
the study ?  24 wives, 12 husbands, 4 daughters, 1 son, 1 mother 
and 1 sister. 
 
Two patients were not able to complete the SeiQol-DW interview, and therefore their QoL 
index at baseline is missing. All patients were able to complete the assessment of symptoms. All 
participants but two completed the psychosocial and spiritual assessment. 
 
At baseline, no differences were found in the two groups for demographics, clinical features, 
disability level (see online supplementary appendix table S1) and the outcome measure (see 
online supplementary appendix table S2), showing that the randomisation was successful. 
 
At T1, after FT had received the SPCS, the mortality in the two groups was the same: 2 patients 
died in the  FT  group  and  2  in  the  ST  group,  during  the  16 weeks. Two patients dropped 
out, both in the FT group: a patient with ALS/MND and a patient with MS, both of whom 
decided not to continue the study for personal reasons after the baseline assessment. 
 
Results of intervention 
 
Outcome measures at T1 revealed a significant improvement ( p<0.05) for the FT group in one 
main outcome, the individual QoL of patients, and in five secondary outcomes, all in the 
physical symptoms: pain, breathlessness, sleep disturbance, intestinal and urinary symptoms 
and mouth discomfort ? (see online supplementary appendix table S3). 
 
Clinical significance: In order to compare the  results between the two groups that could be 
caused by the intervention of the SPCS, new variables were created by subtracting the mean 
results of the test at T0 (baseline) from the ones obtained at T1 (after intervention). These new 
ǀĂƌŝĂďůĞƐ ǁĞƌĞ ĐĂůůĞĚ  ?differĞŶĐĞ ǀĂƌŝĂďůĞƐ ? ĂŶĚ ƌĞƐƵůƚƐ ĂƌĞ ƐŚŽǁŶ ŝŶtable 3. The difference 
reported in percentage was used to assess the clinical significance of the results. These results 
showed a clinical (>20%) improvement of the QoL, pain control, breathlessness and sleep 




Statistical significance: A one-way ANCOVA between-groups analysis was conducted for those 
variables that showed a statistically significant difference between the two groups after the 
intervention (T1). The aim of this test was to determine whether by adjusting these results for 
the covariate represented by the baseline assessment (T0) of the same domains the statistical 
significance was maintained. The seven variables with these characteristics were: QoL and the 
physical symptoms (pain control, breathlessness, sleep disorders, urinary symptoms, intestinal 
symptoms and oral symptoms). The independent variable was the type of intervention: FT/ST. 
The dependent variable was the score on the SEIQoL-DW and the Numerical Rating Scale 
scores for the remaining six symptoms at d ? ?WĂƌƚŝĐŝƉĂŶƚƐ ?ƐĐŽƌĞƐĂƚd ? ?ďĂƐĞůŝŶĞ ?were used as 
the covariate in this analysis. 
ŽŶĨĞƌƌŽŶŝĂĚũƵƐƚŵĞŶƚǁĂƐĂƉƉůŝĞĚƚŽƚŚĞɲǀĂůƵĞƚŚĂƚǁĂƐĐŽŶƐŝĚĞƌĞĚƐŝŐŶŝĨŝĐĂŶƚĂƚ ? ? ? ? ? ? 
 
As shown in table 4, a statistically significant advantage for FT was shown for the QoL, pain, 
breathless- ness, sleep disturbance and bowel symptoms. Figure 2 (loaded as a separate file) 




This study aimed to understand the impact of  an  SPCS on palliative care outcomes of 
people severely affected by neurodegenerative disorders. The main outcomes were the 
individual QoL of  patients  and  the burden of care of their  informal  family  carer.  The results 
show that there was a positive improve- ment in QoL for those patients who received the  
SPCS. The overall QoL was similar to that shown in previous studies as in this study the mean  
SEIQoL-DW was 62, similar to 72,22 7331 for ALS/ MND and 61 for MS21 and 60 for a general 
palliative care population,32 although these results are from a single observation and not over 
time. In this RCT, the sample of patients who received the SPCS scored over 20% higher on the 
SEIQoL index than the control group, and this difference was confirmed statistically. 
 
The other main outcome on the burden of care for families and carers was not found to be 
affected by the provision of the SPCS. This may reflect the long disease progression and that 
families had experienced the burden of caring for the patient for many months or years before 
the SPCS was provided. Moreover, as the SPCS became involved in these later stages, families 
were confronted with discussion of death and dying, as the patients were so ill. This may have 
been difficult for them, so that may have felt that the SPCS added to their psychological 
burdens. 
 
However, symptoms were shown to be significantly improved, both clinically and statistically, 
for pain, breathlessness, sleep disturbance and bowel symptoms. It is likely that these 
improvements had a positive impact on the QoL, and therefore can explain the positive impact 
ŽĨƚŚĞƐĞƌǀŝĐĞŽŶƉĂƚŝĞŶƚƐ ?YŽ> ?dŚĞƐƚƵĚǇŽŶ patients with MS11 showed a significant change 
only in the management of nausea, although there is much anecdotal evidence that SPCS does 
improve symptom management.33 
 
There were positive trends towards improvement of other symptoms and issues, in particular 
social isolation of the patients, all the other physical symptoms, service satisfaction for both 
patients and informal family carers, and a help to find a meaning in the experience of the 
disease. Only for the psychological outcomes was the trend towards a worsening in the treated 
group, although this was not clinically or statistically significant. It is possible that the impact of 
professionals so used to death and dying caused difficulties in coping with patients who often 
think them- selves as chronically ill, rather than terminally ill. Other studies have suggested 
 8 
 
that people with ALS/ MND and other chronic, progressive illnesses may become demoralised 
and less able to accept changes and work on the more complex and difficult psycho- logical 
issues.34 
 
The study also showed that recruitment was possible for an RCT of this nature as only two 
potential participants refused to be enrolled and attrition was low with only two patients 
abandoning the study. The mortality was equal in the two arms. This was shown in the 
previous study on MS and shows that palliative care does not seem to hasten death.15 Thus, it 
would appear that the methodology of the waiting list procedure is feasible and reliable and 
can be used to assess palliative care outcomes in palliative care settings for patients with an 
expected life span of months/years. Low attrition and relatively low missing data confirmed a 
good impact of the study on the participants who adhered to this study and remained in the 
protocol for the follow-up with a very low attrition rate. 
There are limitations in this study as the population was heterogeneous and formed by 
patients affected by different clinical conditions and with different trajectories. Some tools 
were not validated for secondary outcomes, but were chosen to measure specific issues that 
emerged in a previous needs assessment.35 Only one evaluation and no crossover could be 
carried out over time, so we do not know if the improvement in the measured domains is 
maintained. Within the practicality of this study, these issues could not be addressed but 




This study represents one of the first published experiences of assessment and evaluation of the 
impact of an SPCS in non-cancer conditions. Moreover, there  are very limited assessments of 
any palliative care in any patients group, although there has been evidence of early palliative 
care leading to improved QoL and prognosis in lung cancer.36 The lack of evidence of effect on 
ŝŶĨŽƌŵĂů ĐĂƌĞƌƐ ? ǁĞůů-being should be studied in depth. The approach to relatives who have 
been providing care to their beloved for a very long time could be different from that 
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Table 1  ? Clinical requirements indicating advanced disease 
 
General indicators of deterioration in neurological diseases 
ھ Progressive deterioration in physical or cognitive function despite optimal therapy 
ھ Complex symptoms 
ھ Swallowing problems leading to respiratory complications 
ھ Speech problems: dysarthria and progressive dysphasia 
 
Specific clinical indicators for the disease groups 
ALS/MND ھ Evidence of disturbed sleep related to respiratory muscle weakness in 
addition to signs of dyspnoea at rest 
ھ Increased cognitive difficulties/barely intelligible speech 
ھ  Difficulty swallowing poor nutritional status/weight loss 
ھ Needing assistance with ADLs 
ھ Medical complications, eg, pneumonia, sepsis 
ھ A low vital capacity (below 50% of predicted, hypercapnia) 
Multiple sclerosis  ? ?^^A? ? ? 5 
2. Presence of at least one of the following conditions: 
ھ Significant complex symptoms and medical complications 
ھ Dysphagia (swallowing difficulties) admissions with sepsis and 
poor nutritional status 
ھ Communication difficulties, eg, dysarthria+fatigue 
ھ Cognitive impairment 
ھ Breathlessness 
Movement disorders 1. Hoehn and Yahr stage A? ? 
2. No indication for neurosurgical procedures 
3. The presence of 2 or more of the following criteria: 
ھ Drug treatment is less effective or an increasingly complex 
regime of drug treatments 
ھ Reduced independence, need for help with daily living 
ھ Recognition that the condition has become less controlled and 
ůĞƐƐƉƌĞĚŝĐƚĂďůĞǁŝƚŚ “ŽĨĨ ?ƉĞƌŝŽĚƐ 
ھ Dyskinesias, mobility problems and falls 
ھ Swallowing problems 




Adapted from the Gold Standards Framework prognostic indicator guidance. 
















Table 2 Selected domains and outcome measures 
 
 
Outcomes  and general areas Specific domain
 Measurement tool 
 
Primary outcome 1 WĂƚŝĞŶƚƐ ? individual QoL The SEIQoL-DW 
Primary outcome 2 ĂƌĞŐŝǀĞƌƐ ? burden of care CBI 
Physical symptoms ھ Pain     NSR 0-10 
ھ Shortness of breath 
ھ Quality of sleep 
ھ Urinary problems 
ھ Intestinal problems 
ھ Oral symptoms 
Psychological issues ھ Anxiety     HADS25 
ھ Depression 
ھ Feeling abandoned   NSR 0-10 
ھ Coping with the disease 
Social issues ھ Social isolation    NSR 0-10 
ھ Service satisfaction 
Spiritual issues ھ Meaning of the experience   NSR 0-10 
ھ Help from faith 
NRS 0 ?10 
 
NRS 0 ?10Disability (only at baseline) ADL                ھ ADL 
ھ IADL tests26 
Cognitive status Short form of the  
 Mini-mental state test  
                                                                                                                      called AMTS27 
Specific disability scales for the three diagnostic groups  
 ھ ALSFRS-R for patients  
 with ALS/MND 
ھ EDSS for patients with 
MS17 




ADL, activity of daily living; ALS/MND, amyotrophic lateral sclerosis motor neurone disease; ALSFRS-R, 
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; CBI, Caregiver Burden Inventory; AMTS, 
Abbreviated Mental Test Score; EDSS, Expanded Disability Status Scale; HADS, Hospital Anxiety and 
Depression Scale; H&Y, Hoehn and Yahr; IADL, instrumental activity of daily living; MS, multiple 
sclerosis; NRS, Numerical Rating Scales; PD, WĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ ? SEIQoL-DW, Schedule for the 




















ȴŵĞĂŶƐd ?±T0 (SD) 
in FT and ST 
ůŝŶŝĐĂůƐŝŐŶŝĨŝĐĂŶĐĞȴŵĞĂŶƐ
T1±d ? ?&dǀƐ^d ?ȴA? ? 
Statistical significance(p<0.05*) 
Quality of life²SEIQoL-DW index (0±100) 
Higher scores=better QoL 
FT=+12.8 (12.8) 
^dA?AL ? ? ? ? ? ? ? ? ? 
20.19 (20.2%)* 
Pain (0±10) 
Lower score=lower symptom 




Lower score=lower symptom 
&dA?AL ? ? ? ? ? ? ? ? ? 
ST=+0.69 (3.1) 
AL2.26 (22.6%)* 
Sleep disturbance (0±10) 
Lower score=lower symptom 
&dA?AL ? ? ? ? ? ? ? ? ? 
ST=+0.52 (3.2) 
AL2.14 (21.4%)* 
Urinary symptoms (0±10) 
Lower score=lower symptom 
&dA?AL ? ? ? ? ? ? ? ? ? 
^dA?AL ? ? ? ? ? ? ? ? ? 
AL1.74 (17.4%) 
Bowel symptoms (0±10) 
Lower score=lower symptom 
&dA?AL ? ? ? ? ? ? ? ? ? 
ST=+0.17 (3.3) 
AL2.07 (20.7%) 
Oral symptoms (0±10) 
Lower score=lower symptom 
&dA?AL ? ? ? ? ? ? ? ? ? 
ST=+0.43 (3.3) 
AL1.24 (12.4%) 
Feeling abandoned (0±10) 
Higher scores=lower distress 
FT=+0.45 (3.7) 
^dA?AL ? ? ? ? ? ? ? ? ? 
0.67 (6.7%) 
Coping with the disease (0±10) 





Higher scores=higher meaning 
FT=+0.50 (3.6) 
^dA?AL ? ? ? ? ? ? ? ? ? 
1.45 (14.5%) 
Help from faith (0±10) 
Higher scores=better support 
FT=0.0 (1.8) 
^dA?AL ? ? ? ? ? ? ? ? ? 
0.31 (3.1%) 
Sense of social isolation (patient 0±10) 
Higher scores=lower sense of isolation 
FT=+1.35 (3.7) 
^dA?AL ? ? ? ? ? ? ? ? ? 
2.39 (23.9%) 
Service satisfaction (patient 0±10) 
Higher scores=higher satisfaction 
FT=+0.85 (3.8) 
^dA?AL ? ? ? ? ? ? ? ? ? 
1.37 (13.7%) 
Sense of social isolation (carers 0±10) 
Higher scores=lower sense of isolation 
FT=+0.50 (4.4) 
^dA?AL ? ? ? ? ? ? ? ? ? 
0.78 (7.8%) 
Service satisfaction (carers 0±10) 
Higher scores=higher satisfaction 
FT=+1.25 (3.8) 
^dA?AL ? ? ? ? ? ? ? ? ? 
1.34 (13.4%) 
Caregiver burden of care CBI index (0±96) 
Lower score=lower burden of care 
&dA?AL ? ? ? ? ? ? ? ? ? ? 
ST=+0.73 (9.37) 
AL4.93 (5.1%) 
Clinical significance:   
ځ ȴA?ŝƐƚŚĞŶƵŵĞƌŝĐĂůĚŝĨĨĞƌĞŶĐĞŝŶƚŚĞŵĞĂŶƐĐŽƌĞd ?±T0 between the FT and ST groups. 
ځ ȴA?A?ŝƐƚŚĞĚŝĨĨĞƌĞŶĐĞŝŶƚŚĞƉĞƌĐĞŶƚĂŐĞŽĨƚŚĞŵĞĂŶƐĐŽƌĞd ?±T0 between the FT and ST groups. 
± A? ? ?A? is considered as a relevant significant difference. 
± 10±19% is considered as a moderate clinical significance. 
± <10% no clinical difference. 
*Statistical significance: Significant at p<0.05 level. 
CBI, Caregivers Burden Inventory; FT, fast track; SEIQoL-DW, Schedule for the Evaluation of Individual Quality of Life 












Table 4  Analysis of covariance (ANCOVA) results 
 
 
Domain ANCOVA test Significant p<0.007 Partial ɻ2 
  







































































Figure 1 Flow chart of the study loaded as a separate file (GP, general practitioner; 


































Figure 2 Overall results loaded as a separate file (ANCOVA, analysis of covariance; FT, fast 
track; QoL, quality of life ST, standard track. 
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